Generic placeholder image

Infectious Disorders - Drug Targets

Author(s): Esmaeil Mehraeen, Zeinab Najafi, Bagher Hayati, Mohammad Javaherian, Sajad Rahimi, Omid Dadras, SeyedAhmad SeyedAlinaghi*, Maryam Ghadimi and Jean-Marc Sabatier

DOI: 10.2174/1871526521666210726150435

DownloadDownload PDF Flyer Cite As
Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review

Article ID: e260721194968 Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

Introduction: COVID-19 is the third rising epidemic in the 21st century that quickly turned into a worldwide pandemic. Many clinical studies have been achieved to investigate treatments to confront COVID-19. Therefore, we conducted a systematic review to describe the recent treatment strategies to treat COVID-19 patients.

Methods: A systematic search was performed in the databases of PubMed, Scopus, Embase, Science direct, Up to date, and Web of Science using the keywords of Coronavirus, COVID-19, SARS-CoV-2, Novel Coronavirus, 2019-nCoV, Treatment, Medicine, Therapy, Intervention, Drug, Medications, and Cure. All the relevant articles were collected from December 2019 to July 2020.

Results: We included 58 studies including 38 articles (eleven reviews, ten editorial documents, three case reports, one mix method, one cohort study), and 19 published clinical trials. Review of studies showed that Lopinavir/Ritonavir (n=16), Remdesivir (n=13), Convalescent plasma (n=11), Chloroquine (n=11), Ribavirin (n=9), Hydroxychloroquine sulfate (n=8), Traditional Chinese Medicine (TCM) (n=8), and Arbidol (n=7), were the most frequently therapies used to treat COVID-19 patients.

Conclusion: In the absence of definitive treatment protocols, recently proposed approaches have appeared to be an effective therapy for accelerating the recovery of COVID-19 patients. Some of these treatments may have been in the early stages of testing. However, future preclinical and clinical trials are warranted to validate findings.

Keywords: Coronavirus, COVID-19, treatment, medicine, intervention, antiviral, COVID-19 therapy.

Graphical Abstract

[1]
Ghiasvand F. SeyedAlinaghi S, Tirgar S, Salehi MR, Moradmand-Badie B., Salehi MR, Moradmand-Badie B. A patient with covid-19 pneumonia presenting with plural effusion: A case report. Trop Med Infect Dis 2021; 21(6) ,e170721187994
[PMID: 33200715]
[2]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[3]
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[4]
Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H. SeyedAlinaghi S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. Eur Arch Otorhinolaryngol 2021; 278(2): 307-12.
[http://dx.doi.org/10.1007/s00405-020-06120-6] [PMID: 32556781]
[5]
Mehraeen E, Hayati B, Saeidi S, Heydari M, Seyed Alinaghi S. Selfcare instructions for people not requiring hospitalization for coronavirus disease 2019 (covid-19). Arch Clin Infect Dis 2020; 15(COVID- 19): e102978.
[6]
Asadollahi Amin AGF, Rezaei H. SeyedAlinaghi S. Asymptomatic SARS-CoV-2ý infection with lung involvement accidentally found on chest CT scan: A case report. Trop Med Infect Dis 2020; 5(2): 56.
[http://dx.doi.org/10.3390/tropicalmed5020056] [PMID: 32272630]
[7]
Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA 2020; 323(11): 1092-3.
[http://dx.doi.org/10.1001/jama.2020.1623] [PMID: 32031568]
[8]
Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect 2020; 22(2): 69-71.
[http://dx.doi.org/10.1016/j.micinf.2020.01.004] [PMID: 32032682]
[9]
Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med 2020; 201(4): 7-P8.
[http://dx.doi.org/10.1164/rccm.2014P7] [PMID: 32004066]
[10]
Zhang Q, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol 2020; 92(6): 540-5.
[http://dx.doi.org/10.1002/jmv.25733] [PMID: 32108352]
[11]
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; 57: 279-83.
[http://dx.doi.org/10.1016/j.jcrc.2020.03.005] [PMID: 32173110]
[12]
McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019. Available from:. www.uptodate.com
[13]
Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 2020; 35(14) ,e149
[http://dx.doi.org/10.3346/jkms.2020.35.e149] [PMID: 32281317]
[14]
Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health 2020; 9 ,100128
[http://dx.doi.org/10.1016/j.onehlt.2020.100128] [PMID: 32258351]
[15]
Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing) 2020; 6(10): 1192-8.
[http://dx.doi.org/10.1016/j.eng.2020.03.007] [PMID: 32346491]
[16]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[17]
Cao W, Liu X, Bai T, Fan H, Hong K, Song H, Eds. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 2019; 7(3): ofaa102.
[http://dx.doi.org/10.1093/ofid/ofaa102]
[18]
Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci 2020; 24(7): 4016-26.
[PMID: 32329877]
[19]
Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for covid- 19: A randomized clinical trial. medRxiv 2020; 20037432.
[http://dx.doi.org/10.1101/2020.03.17.20037432]
[20]
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55(4) ,105932
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105932] [PMID: 32145363]
[21]
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20(4): 398-400.
[http://dx.doi.org/10.1016/S1473-3099(20)30141-9] [PMID: 32113510]
[22]
Chang R, Sun W-Z. Repositioning chloroquine as ideal antiviral prophylactic against covid-19-time is now. Drug Discov Today 2020. ,2020030279
[23]
Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, et al. Thalidomide combined with low-dose glucocorticoid in the treatment of covid-19 pneumonia. Int J Infect Dis 2021; 103: 507-13.
[http://dx.doi.org/10.1016/j.ijid.2020.12.023]
[24]
Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care 2020; 24(1): 91.
[http://dx.doi.org/10.1186/s13054-020-2818-6] [PMID: 32178711]
[25]
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14(1): 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[26]
Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. British Medical Journal Publishing Group 2020; p. 368.
[27]
Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020; 19(5) ,102523
[http://dx.doi.org/10.1016/j.autrev.2020.102523] [PMID: 32205186]
[28]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[29]
Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol 2020; 215 ,108409
[http://dx.doi.org/10.1016/j.clim.2020.108409] [PMID: 32276137]
[30]
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1) ,105949
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[31]
Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 2020; 7(1): 1-10.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID: 31928528]
[32]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[33]
Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020; 395(10238): 1695-704.
[http://dx.doi.org/10.1016/S0140-6736(20)31042-4] [PMID: 32401715]
[34]
Izzedine H, Jhaveri KD, Perazella MA. COVID-19 therapeutic options for patients with kidney disease. Kidney Int 2020; 97(6): 1297-8.
[http://dx.doi.org/10.1016/j.kint.2020.03.015] [PMID: 32317113]
[35]
Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv 2020; 20038984.
[http://dx.doi.org/10.1101/2020.03.19.20038984]
[36]
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149-50.
[http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID: 32127666]
[37]
Lim J, Jeon S, Shin H-Y, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020; 35(6) ,e79
[http://dx.doi.org/10.3346/jkms.2020.35.e79] [PMID: 32056407]
[38]
Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 2020; 26(4): 243-50.
[http://dx.doi.org/10.1007/s11655-020-3192-6] [PMID: 32065348]
[39]
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020; 92(7): 814-8.
[http://dx.doi.org/10.1002/jmv.25801] [PMID: 32253759]
[40]
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020; 14(1): 69-71.
[http://dx.doi.org/10.5582/bst.2020.01020] [PMID: 31996494]
[41]
Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol 2020; 214 ,108408
[http://dx.doi.org/10.1016/j.clim.2020.108408] [PMID: 32247038]
[42]
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol 2020; 92(9): 1475-83.
[http://dx.doi.org/10.1002/jmv.25961] [PMID: 32356910]
[43]
Ren JHZA, Jun Wang Xi. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020; 155 ,104768
[http://dx.doi.org/10.1016/j.phrs.2020.104768] [PMID: 32222346]
[44]
Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica 2020; e40: 44
[45]
Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020; 323(16): 1561-2.
[http://dx.doi.org/10.1001/jama.2020.4940] [PMID: 32219429]
[46]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 323(18): 1824-36.
[PMID: 32282022]
[47]
Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol 2020; 52(1): 1-5.
[http://dx.doi.org/10.4103/ijp.IJP_119_20] [PMID: 32201439]
[48]
Sarma P, Kaur H, Kumar H, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol 2020; 92(7): 776-85.
[http://dx.doi.org/10.1002/jmv.25898] [PMID: 32297988]
[49]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[50]
Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20(4): 400-2.
[http://dx.doi.org/10.1016/S1473-3099(20)30132-8] [PMID: 32113509]
[51]
Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua jie he he hu xi za 2020; 43(0): E014.
[PMID: 32061198]
[52]
Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients withcovid-19 with convalescent plasma. JAMA 2020; 323(16): 1582-9.
[http://dx.doi.org/10.1001/jama.2020.4783] [PMID: 32219428]
[53]
Syal K. COVID-19: Herd immunity and convalescent plasma transfer therapy. J Med Virol 2020; 92(9): 1380-2.
[http://dx.doi.org/10.1002/jmv.25870] [PMID: 32281679]
[54]
Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang 2020; 115(6): 488-94.
[http://dx.doi.org/10.1111/vox.12926] [PMID: 32240545]
[55]
Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; 368: m1256.
[http://dx.doi.org/10.1136/bmj.m1256] [PMID: 32217555]
[56]
To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect Dis 2020; 20(5): 565-74.
[http://dx.doi.org/10.1016/S1473-3099(20)30196-1] [PMID: 32213337]
[57]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[58]
Xu X, Han M, Li T, et al. Effective treatment of severe covid-19 patients with tocilizumabChinaXiv
[59]
Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (sars-cov-2): A review and perspective. Int J Biol Sci 2020; 16(10): 1708-17.
[http://dx.doi.org/10.7150/ijbs.45538] [PMID: 32226288]
[60]
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[61]
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46(4): 586-90.
[http://dx.doi.org/10.1007/s00134-020-05985-9] [PMID: 32125455]
[62]
Zhang L, Pang R, Xue X, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY) 2020; 12(8): 6536-42.
[http://dx.doi.org/10.18632/aging.103102] [PMID: 32320384]
[63]
Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020; 75(7): 1667-70.
[http://dx.doi.org/10.1093/jac/dkaa114] [PMID: 32196083]
[64]
Zhong H, Wang Y, Zhang Z-L, et al. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol Res 2020; 157 ,104872
[http://dx.doi.org/10.1016/j.phrs.2020.104872] [PMID: 32360583]
[65]
Kumar Y, Singh H, Patel CN. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Public Health 2020; 13(9): 1210-23.
[http://dx.doi.org/10.1016/j.jiph.2020.06.016] [PMID: 32561274]
[66]
Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020; 253 ,117592
[http://dx.doi.org/10.1016/j.lfs.2020.117592] [PMID: 32222463]
[67]
Peele KA, Potla Durthi C, Srihansa T, et al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Inform Med Unlocked 2020; 19 ,100345
[http://dx.doi.org/10.1016/j.imu.2020.100345] [PMID: 32395606]
[68]
Shahab S, Sheikhi M, Alnajjar R, Saud SA, Khancheuski M, Strogova A. DFT investigation of atazanavir as potential inhibitor for 2019-nCoV coronavirus M protease. J Mol Struct 2021; 1228 ,129461
[http://dx.doi.org/10.1016/j.molstruc.2020.129461] [PMID: 33100379]
[69]
Shahab S, Sheikhi M. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study. Curr Mol Med 2021; 21(8): 645-54.
[http://dx.doi.org/10.2174/1566524020666200521075848] [PMID: 32436829]
[70]
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9(396) ,eaal3653
[http://dx.doi.org/10.1126/scitranslmed.aal3653] [PMID: 28659436]
[71]
SeyedAlinaghi S, Ghadimi M, Hajiabdolbaghi M, et al. Prevalence of COVID-19-like symptoms among people living with HIV, and using antiretroviral therapy for prevention and treatment. Curr HIV Res 2020; 18(5): 373-80.
[http://dx.doi.org/10.2174/1570162X18666200712175535] [PMID: 32652912]
[72]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[73]
Luo Y, Wang C-Z, Hesse-Fong J, Lin J-G, Yuan C-S. Application of Chinese medicine in acute and critical medical conditions. Am J Chin Med 2019; 47(6): 1223-35.
[http://dx.doi.org/10.1142/S0192415X19500629] [PMID: 31505937]
[74]
Ghiasvand F, Ghadimi M, Sadr S, et al. COVID-19 treatment success after repeat courses of azithromycin: a report of three cases. Infect Disord Drug Targets 2021; 21(6) ,e170721188439
[http://dx.doi.org/10.2174/1871526520999201126203510] [PMID: 33243134]
[75]
Jamali MSS, Zarezade B, Koolaji S, et al. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. Eur J Med Res 2021; 26(1): 20.
[http://dx.doi.org/10.1186/s40001-021-00490-1] [PMID: 33573699]
[76]
Sekhavati E, Jafari F. SeyedAlinaghi S, et al Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Int J Antimicrob Agents 2020; 56(4) ,106143
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106143] [PMID: 32853672]